Replies to post #295826 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

Looks like cancer drug Nilotinib may be a competitor if Isradipine does well, except it costs 10K/month.

https://parkinsonsdisease.net/news/cancer-drug-nilotinib-may-slow-progression-parkinsons/

[dr_lowenstein]

yes, it is the drug that is being used in the trial (note singular). No reason provided as to that choice. If the trail is positive it could benefit makers of generic isradipine, two things are likely :1. the bulk of those new sales will go to the company that currently owns the most market share and that is NOT elite and 2. the entrants that have previously discontinued doe to crappy sales will come back in,
In addition it is also likely that a significant portion will be siphoned off to other CCBs because as I have posted there is evidence that the others may confer these same benefits, if there are any